Audit Committee

Home»Corporate Governance»Functional Committee»Audit Committee

Audit Committee

  • i.Remuneration Audit meetings held (A) in the previous years and the attendance of members:
  • Title Name Attendance in Person (B) Attendance Through Proxy Attendance Rate (B/A) (%) Remarks
    Chairman Dr. Wei-Ta Pan 5 0 100.0 Re-appointed on
    2019/06/21
    Committee Member Dr. Pisin Chen 5 0 100.0 Re-appointed on
    2019/06/21
    Committee Member Hung Ching Lee 5 0 100.0 Newly appointed on
    2019/06/21
  • On March 31, 2016, the Board approved the “Audit Committee Charter” as a reference to establish the Audit Committee to supervise the fair expression of the Company’s financial statements, the selection or dismissal of certified public accountants (CPAs) and assessment of their independence and performance, effective implementation of the internal control, and legal compliance of the Company, as well as to control the inherent and potential risks.
  • The 1st Audit Committee was established on June 24, 2016 to replace the duties and functions of Supervisors. The Audit Committee consists of three independent Directors as the ex officio members and Dr. Wei-Ta Pan was elected to convene the Committee and served as the Chair of Committee meetings.
  • The 2nd Audit Committee was re-elected to accompany the newly elected BoD on June 21, 2019 with three independent Directors elected as the Audit Committee members, including Dr. Wei-Ta Pan, Dr. Pisin Chen and Mr. Hung Ching Lee. While, Dr. Wei-Ta Pan was elected to convene the Committee and served as the Chair of Committee meetings. The tenure is for three years from July 12, 2019 to June 20, 2022, the same termination date as the end of the BoD term.
  • ii. Additional Disclosure:
  • A. The date of the meeting, session, content of the motion, expressed by all independent Directors, and the Company’s response to such opinions shall be specified when the operation of Audit Committee is under any one of the following circumstances:
  • (1) Matters specified in Article 14-3 of the Securities and Exchange Act:
  • All independent Directors had attended the committee meetings and approved all matters specified in Article 14-3 of the Securities and Exchange Act without objection in FY2019 and as of the date of this report's publication.
  • (2) Matters other than above stated which were not approved by the Audit Committee but resolved by over two thirds of all Directors: NA.
  • B. Execution of independent Directors’ avoidance of motions in conflict of interests:
  • No avoidance of motions in conflict of interests was reported in FY2019.
  • C. Communication between the Audit Committee, Independent Directors, the Chief Internal Auditor and accountants:
  • Please refer to: https://www.quantatw.com/Quanta/english/corporategovernance/audit.aspx